Saffron Walden, UK; 9 July 2009 - Taking place at The Nucleus conference centre, Chesterford Research Park, Saffron Walden, UK from 22 - 23 September 2009, the new scientific conference ‘Novel Applications and Cutting Edge Technologies for GPCR Screening and Profiling’ will provide delegates with the opportunity to hear from thought leaders and share experiences within this rapidly developing field.

Keynote speaker Fiona Marshall (Chief Scientific Officer, Heptares Therapeutics) will talk about “Structure-based Drug Discovery for GPCR Targets”.

The meeting will highlight the latest technological developments and tools available for drug discovery on GPCR receptors, with key opinion leaders presenting their experience of generating high-quality screening data. Furthermore, case studies will be described where flexible assay formats and newly available tools have enhanced throughput for successful compound screening. Delegates are encouraged to present posters.

This meeting is being sponsored by three pioneering companies in GPCR research, BioFocus DPI (a provider of gene-to-drug candidate discovery services), DiscoveRx (a leading provider of cell-based assays and services for GPCR, Kinases, NHRs and Proteases) and MDS Analytical Technologies (sets the gold standard for high-performance bioanalytical measurement systems).

Attendance is free but is limited to 150 delegates. For more information and to register as well as book pre-conference updates, please visit www.BioFocusDPI.com/GPCR.

About BioFocus DPI

BioFocus DPI aims to expand its partners’ drug pipelines by accelerating the gene-to-candidate discovery process.  This is achieved through a comprehensive discovery platform, which includes target discovery in human primary cells, focused as well as diverse compound libraries, in vitro and cell-based screening, structural biology, medicinal chemistry, ADME/PK services, supported by unique chemogenomic and informatics tools, and compound library acquisition, storage and distribution services.  As the service division of Galapagos, BioFocus DPI has over 250 employees in four countries worldwide.  For more information, visit www.biofocusdpi.com.

About DiscovRx

Founded in 2000, DiscoveRx is a privately held, venture-backed company headquartered in Fremont, California, with an additional office in Birmingham, England. The Company pioneered the use of ß-Galactosidase enzyme fragment complementation in biochemical and cell based assays for discovery research, and holds extensive intellectual property in this area. DiscoveRx is dedicated to the development and commercialization of innovative solutions to study GPCRs, Kinases and other major drug target classes, and many of their innovative products have been widely adopted in pharmaceutical and biotech drug screening laboratories worldwide. Please visit www.discoverx.com to get additional information regarding DiscoveRx products..

About MDS Analytical Technologies

MDS Analytical Technologies, a business unit of MDS Inc., is focused on the research, design, manufacture and marketing of state-of-the-art tools for mass-spectrometry, drug discovery and bioresearch. MDS Analytical Technologies' products are designed to help accelerate the complex process of discovering and developing new drug compounds, and are sold to research scientists around the world. The mass-spectrometer product lines are also sold globally through joint ventures with two of the world's leading analytical instrumentation and life-sciences companies, Life Technologies Corporation and PerkinElmer, Inc. Find out more at www.mdssciex.com or www.moleculardevices.com..